top of page
Derivative products
AR101 Derivative -2
Supplement for prevention stroke (Transfer from ITRI)
AR101
-
The infarct volume of each group 24hr after MCAO. The volume was greatly decreased in rats treated with pure compounds extract from AR101.
-
Active compounds were verified by animal study.
Title: Use of antrodia camphorata for the manufacture of a medicament for treating stroke, decreasing nerve injury or stroke prognosis
Publication No.: I461204-TW
AR101 Derivative -3
ALZHEIMER’S DISEASE
AR106
-
AR106 administration improved the performance of water maze in APP/PS1 mice and the impairment of nesting behavior.
-
AR106 reduces the amyloid plaques in Alzheimer’s mice
By 2050, 13.8 million people in the United States who are aged 65 or older live with AD
13.8 M
$14.8B
Reaching sales of $14.8 billion across the 7MM.
AR101 Derivative -4
Liver fibrosis
AR120
-
Decrease AGT and ALT
-
Improve the inflammation and fibrosis of liver in Vivo
-
Decrease the fatty liver significantly.
-
Decrease the fatty liver cirrhosis significantly.
-
Inhibit the Entry and Release of the HBV.
$28.1B
Liver fibrosis therapeutics market to rise to $28.1b by 2026, says GlobalData
CAGR 10.8%
Liver fibrosis market is expected to register a CAGR of 10.8% during the forecast period 2018 to 2026.
Treatment of liver fibrosis:
-
Chronic liver disease: ACE inhibitor
-
Hepatitis C virus: a-Tocopherol or interferon-alpha
-
Nonalcoholic steatohepatitis : PPAR-alpha agonist
-
Can’t be Reverse accroding to the current clinical care
AR101 Derivative -5
Cardiovascular disease
AR101
-
Attenuate aortic lesions in high fat fed animal models.
-
Significantly decrease the Infarct Volume from stroke
-
AR compounds are NOT anticoagulant.
-
MOA is different with Statin.
-
AR compounds can be combined with t-PA or stent retriever at the same time.
$ 7.2B
Global Acute Ischemic Stroke Drug Forecast indicates Sales of Drugs in the AIS Market (Including TIA) were approximately $7.2B in 2017.
$ 146.4B
The cardiovascular disease market, which includes hypertension, dyslipidaemia and thrombotic events, is set to grow to $146.4 billion by 2022.
bottom of page